AstraZeneca Refocuses On Risk Management, Elevates Development Oversight

Former Exec VP-Product Strategy & Licensing John Patterson will assume the board-level position of exec director-development effective Jan. 1. Regulatory affairs overhaul will include a review of ongoing Phase III programs for Galida, Cerovive and Symbicort.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet